Search Beyond News…

Slone Partners appoints Amer Mirza, PhD as Chief Scientific Officer at Prolynx to strengthen R&D for its ultra‑long‑acting obesity therapeutics portfolio

Executive summary: Slone Partners named Amer Mirza, PhD, as Chief Scientific Officer at Prolynx, a company developing ultra‑long‑acting medicines for obesity and metabolic disorders. The hire adds senior scientific leadership to Prolynx’s R&D effort, potentially accelerating progress on its obesity drug pipeline in a competitive therapeutic area.

Who is involved: Slone Partners (executive search firm), Amer Mirza, PhD (appointee), Prolynx (biotechnology company).

Likely next: Prolynx is expected to advance its ultra‑long‑acting obesity programs under Mirza’s leadership, with further R&D updates anticipated later in 2026.

Slone Partners, a nationwide executive search firm focused on life sciences and healthcare, has placed Amer Mirza, PhD, as the new Chief Scientific Officer of Prolynx. The appointment is intended to drive the research and development execution of Prolynx’s pipeline of ultra‑long‑acting medicines targeting obesity and related metabolic conditions. No financial terms or additional details about Mirza’s compensation were disclosed in the announcement.

Timeline

Analysis — what this means

Likely next events

Sectors affected

Historical parallels

Key entities

Sources

Browse the full archive →